JOP20200023A1 - مركبات حلقية لولبية وطرق تصنيعها واستخدامها - Google Patents
مركبات حلقية لولبية وطرق تصنيعها واستخدامهاInfo
- Publication number
- JOP20200023A1 JOP20200023A1 JOP/2020/0023A JOP20200023A JOP20200023A1 JO P20200023 A1 JOP20200023 A1 JO P20200023A1 JO P20200023 A JOP20200023 A JO P20200023A JO P20200023 A1 JOP20200023 A1 JO P20200023A1
- Authority
- JO
- Jordan
- Prior art keywords
- making
- methods
- same
- compounds
- spirocycle
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762551721P | 2017-08-29 | 2017-08-29 | |
| PCT/US2018/048372 WO2019046318A1 (en) | 2017-08-29 | 2018-08-28 | SPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20200023A1 true JOP20200023A1 (ar) | 2020-02-02 |
Family
ID=65527860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2020/0023A JOP20200023A1 (ar) | 2017-08-29 | 2018-08-28 | مركبات حلقية لولبية وطرق تصنيعها واستخدامها |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US11142526B2 (enExample) |
| EP (1) | EP3675847B1 (enExample) |
| JP (1) | JP7257387B2 (enExample) |
| KR (1) | KR20200046061A (enExample) |
| CN (1) | CN111050765B (enExample) |
| AU (1) | AU2018323459A1 (enExample) |
| BR (1) | BR112020004101A2 (enExample) |
| CA (1) | CA3072923A1 (enExample) |
| CL (1) | CL2020000462A1 (enExample) |
| CO (1) | CO2020001724A2 (enExample) |
| CR (1) | CR20200089A (enExample) |
| DO (1) | DOP2020000039A (enExample) |
| EA (1) | EA202090312A1 (enExample) |
| EC (1) | ECSP20013337A (enExample) |
| ES (1) | ES2952332T3 (enExample) |
| GE (2) | GEP20217327B (enExample) |
| IL (1) | IL272580B (enExample) |
| JO (1) | JOP20200023A1 (enExample) |
| MA (1) | MA50041A (enExample) |
| MX (1) | MX2020002251A (enExample) |
| NI (1) | NI202000014A (enExample) |
| PE (1) | PE20200664A1 (enExample) |
| PH (1) | PH12020500372A1 (enExample) |
| SG (1) | SG11202001022TA (enExample) |
| UA (1) | UA126685C2 (enExample) |
| WO (1) | WO2019046318A1 (enExample) |
| ZA (1) | ZA202001208B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ627750A (en) | 2012-01-06 | 2016-11-25 | Abide Therapeutics Inc | Carbamate compounds and of making and using same |
| US10781211B2 (en) | 2016-05-12 | 2020-09-22 | Lundbeck La Jolla Research Center, Inc. | Spirocycle compounds and methods of making and using same |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| UA126685C2 (uk) | 2017-08-29 | 2023-01-11 | Луннбек Ла-Холья Рісьоч Сенте, Інк. | Сполуки, які є модуляторами magl, і способи їх отримання і застосування |
| RU2020107039A (ru) | 2017-08-29 | 2021-09-30 | Лундбекк Ла-Хойя Рисерч Сентер, Инк. | Спироциклические соединения и способы их получения и применения |
| KR20220034104A (ko) * | 2019-07-09 | 2022-03-17 | 에프. 호프만-라 로슈 아게 | 신규 헤테로고리 화합물 |
| WO2022043284A1 (en) * | 2020-08-26 | 2022-03-03 | F. Hoffmann-La Roche Ag | Heterocyclic compounds useful as magl inhibitors |
| TWI904281B (zh) * | 2020-11-13 | 2025-11-11 | 丹麥商Ｈ 朗德貝克公司 | Magl抑制劑 |
| IL313987A (en) | 2021-12-29 | 2024-08-01 | Psy Therapeutics Inc | Inhibiting monoacylglycerol lipase (magl) |
| WO2023213854A1 (en) | 2022-05-04 | 2023-11-09 | H. Lundbeck A/S | Crystalline form of 1,1,1,3,3,3-hexafluoropropan-2-yl (s)-1-(pyridazin-3-ylcarbamoyl)-6 azaspiro[2.5]octane-6-carboxylate as monoacylglycerol lipase inhibitor. |
| WO2024168426A1 (en) | 2023-02-13 | 2024-08-22 | Apogee Pharmaceuticals, Inc. | Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002070523A1 (en) * | 2001-03-07 | 2002-09-12 | Pfizer Products Inc. | Modulators of chemokine receptor activity |
| JPWO2008023720A1 (ja) | 2006-08-23 | 2010-01-14 | アステラス製薬株式会社 | ウレア化合物又はその塩 |
| US20110071180A1 (en) | 2008-03-05 | 2011-03-24 | Targacept, Inc. | Sub-type selective amides of diazabicycloalkanes |
| FR2941696B1 (fr) | 2009-02-05 | 2011-04-15 | Sanofi Aventis | Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique |
| US20120083476A1 (en) | 2009-06-05 | 2012-04-05 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
| CN102575076B (zh) | 2009-09-29 | 2014-08-20 | 普立万公司 | 具有模拟金属或珠光外观的聚酯制品 |
| ME03452B (me) | 2009-10-23 | 2020-01-20 | Janssen Pharmaceutica Nv | Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora |
| WO2011109277A1 (en) | 2010-03-04 | 2011-09-09 | Merck Sharp & Dohme Corp. | Positive allosteric modulators of mglur2 |
| FR2960875B1 (fr) * | 2010-06-04 | 2012-12-28 | Sanofi Aventis | Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique |
| EP2444084A1 (en) | 2010-10-21 | 2012-04-25 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Use of PI3K inibitors for the treatment of obesity |
| NZ627750A (en) * | 2012-01-06 | 2016-11-25 | Abide Therapeutics Inc | Carbamate compounds and of making and using same |
| PL2900669T3 (pl) | 2012-09-25 | 2020-01-31 | F. Hoffmann-La Roche Ag | Pochodne heksahydropirolo[3,4-C]pirolu i związki pokrewne jako inhibitory autotaksyny (ATX) oraz inhibitory produkcji kwasu lizofosfatydowego (LPA) do leczenia np. chorób nerek |
| US9828379B2 (en) | 2013-07-03 | 2017-11-28 | Abide Therapeutics, Inc. | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof |
| WO2015179559A2 (en) * | 2014-05-21 | 2015-11-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| WO2016149401A2 (en) * | 2015-03-18 | 2016-09-22 | Abide Therapeutics, Inc. | Piperazine carbamates and methods of making and using same |
| MX375424B (es) | 2015-07-31 | 2025-03-06 | Pfizer | Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1,1,1-trifluoro-4- hidroxibutan-2-il carbamato como inhibidores de magl |
| WO2017087858A1 (en) | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| UY37174A (es) | 2016-03-31 | 2017-10-31 | Takeda Pharmaceuticals Co | Un compuesto heterocíclico que tiene una acción inhibidora de monoacilglicerol lipasa |
| US10781211B2 (en) | 2016-05-12 | 2020-09-22 | Lundbeck La Jolla Research Center, Inc. | Spirocycle compounds and methods of making and using same |
| JOP20190049A1 (ar) | 2016-09-23 | 2019-03-20 | Bial Portela & C? S A | مثبطات دوبامين-b-هيدروكسيلاز |
| CA3043609A1 (en) | 2016-11-16 | 2018-05-24 | Abide Therapeutics, Inc. | Pharmaceutical formulations |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JOP20190106A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JOP20190105A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| PL3541807T3 (pl) | 2016-11-16 | 2022-01-17 | H. Lundbeck A/S | Krystaliczna postać inhibitora magl |
| RU2020107039A (ru) | 2017-08-29 | 2021-09-30 | Лундбекк Ла-Хойя Рисерч Сентер, Инк. | Спироциклические соединения и способы их получения и применения |
| UA126685C2 (uk) | 2017-08-29 | 2023-01-11 | Луннбек Ла-Холья Рісьоч Сенте, Інк. | Сполуки, які є модуляторами magl, і способи їх отримання і застосування |
-
2018
- 2018-08-28 UA UAA202001526A patent/UA126685C2/uk unknown
- 2018-08-28 MX MX2020002251A patent/MX2020002251A/es unknown
- 2018-08-28 AU AU2018323459A patent/AU2018323459A1/en not_active Abandoned
- 2018-08-28 GE GEAP201815281A patent/GEP20217327B/en unknown
- 2018-08-28 JP JP2020512586A patent/JP7257387B2/ja active Active
- 2018-08-28 SG SG11202001022TA patent/SG11202001022TA/en unknown
- 2018-08-28 KR KR1020207008312A patent/KR20200046061A/ko not_active Ceased
- 2018-08-28 GE GEAP202115281A patent/GEAP202115281A/en unknown
- 2018-08-28 EP EP18850498.9A patent/EP3675847B1/en active Active
- 2018-08-28 CA CA3072923A patent/CA3072923A1/en active Pending
- 2018-08-28 PE PE2020000296A patent/PE20200664A1/es unknown
- 2018-08-28 EA EA202090312A patent/EA202090312A1/ru unknown
- 2018-08-28 BR BR112020004101-7A patent/BR112020004101A2/pt not_active IP Right Cessation
- 2018-08-28 MA MA050041A patent/MA50041A/fr unknown
- 2018-08-28 US US16/642,717 patent/US11142526B2/en active Active
- 2018-08-28 ES ES18850498T patent/ES2952332T3/es active Active
- 2018-08-28 CR CR20200089A patent/CR20200089A/es unknown
- 2018-08-28 CN CN201880056725.9A patent/CN111050765B/zh active Active
- 2018-08-28 JO JOP/2020/0023A patent/JOP20200023A1/ar unknown
- 2018-08-28 IL IL272580A patent/IL272580B/en unknown
- 2018-08-28 WO PCT/US2018/048372 patent/WO2019046318A1/en not_active Ceased
-
2020
- 2020-02-14 CO CONC2020/0001724A patent/CO2020001724A2/es unknown
- 2020-02-21 EC ECSENADI202013337A patent/ECSP20013337A/es unknown
- 2020-02-21 DO DO2020000039A patent/DOP2020000039A/es unknown
- 2020-02-24 PH PH12020500372A patent/PH12020500372A1/en unknown
- 2020-02-24 NI NI202000014A patent/NI202000014A/es unknown
- 2020-02-25 CL CL2020000462A patent/CL2020000462A1/es unknown
- 2020-02-26 ZA ZA2020/01208A patent/ZA202001208B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020500371A1 (en) | Spirocycle compounds and methods of making and using same | |
| PH12020500372A1 (en) | Spirocycle compounds and methods of making and using same | |
| PH12019502646A1 (en) | Pyrazole magl inhibitors | |
| PH12019501079A1 (en) | Magl inhibitors | |
| MX2017011997A (es) | Carbamatos de piperacina y metodos de preparacion y uso. | |
| MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
| ZA201906111B (en) | Cyclic di-nucleotides compounds for the treatment of cancer | |
| PH12019501097A1 (en) | Magl inhibitors | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| GB2541571A (en) | Pharmaceutical compositions | |
| PH12019501102A1 (en) | Magl inhibitors | |
| EA201891200A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| WO2015179559A3 (en) | Pyrazole compounds and methods of making and using same | |
| MY192927A (en) | Fused bicyclic compounds for the treatment of disease | |
| MX2018004674A (es) | Moduladores de interacción de sestrina-gator2 y sus usos. | |
| MX369623B (es) | Compuestos biciclicos fusionados para el tratamiento de enfermedades. | |
| EP4650000A3 (en) | High concentration formulation | |
| EP4417262A3 (en) | Combination therapy | |
| NZ756915A (en) | Dual magl and faah inhibitors | |
| AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
| MX2020008195A (es) | Compuestos para el tratamiento del dolor. | |
| MX2020012990A (es) | Formulaciones de tegavivint y compuestos relacionados. | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| MY178960A (en) | Hiv treatment formulation of atazanavir and cobicistat | |
| MX370897B (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades, |